Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2013

Open Access 01-02-2013 | Original Article

Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy

Authors: Yukihiro Wada, Hiroaki Ogata, Yui Takeshige, Akiko Takeshima, Noriyo Yoshida, Masahiro Yamamoto, Hidetoshi Ito, Eriko Kinugasa

Published in: Clinical and Experimental Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Immunoglobulin (Ig) A nephropathy (IgAN) is characterized by mesangial deposits of IgA1 and C3, often with co-deposits of IgG. We attempted to clarify the clinical significance of mesangial IgG deposition in patients with IgAN.

Methods

We retrospectively reviewed 57 patients who were diagnosed with IgAN on the basis of pathological examination of renal biopsy specimens obtained between October 2006 and December 2010. Subjects were divided into two groups: IgA+IgG deposition (IgA-IgG) group (n = 29) and IgA deposition alone (IgA) group (n = 28). The study outcome was complete remission (CR), defined as negative proteinuria by dipstick urinalysis and urinary erythrocytes of less than 1–4/high-power field.

Results

Proteinuria was greater in the IgA-IgG group than the IgA group (1.1 ± 0.8 vs. 0.7 ± 0.6 g/day, Mann–Whitney U test, P = 0.042). Capillary wall IgA deposits were noted more frequently in the IgA-IgG group than the IgA group (59 vs. 11 %, Fisher’s exact test, P = 0.014). During the median follow-up period of 33.3 months (range 6–55 months) in the 57 patients, we observed CR in 24 cases (42.1 %). After the start of treatment, urinary abnormalities disappeared earlier in the IgA group than in the IgA-IgG group (log rank test, P = 0.012). Cox’s regression model showed that IgG deposition reduced the hazard ratio for CR (hazard ratio 0.35; 95 % confidence interval 0.14–0.82, P = 0.014). Therefore, IgG deposition is a risk factor for persistent urinary abnormalities.

Conclusion

Mesangial IgG deposition is associated with more severe clinical features in patients with IgAN.
Literature
2.
go back to reference Tomino Y, Sakai H. Special study group (IgA nephropathy) on progressive glomerular disease. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93–7.PubMedCrossRef Tomino Y, Sakai H. Special study group (IgA nephropathy) on progressive glomerular disease. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93–7.PubMedCrossRef
3.
go back to reference Emancipator SN. IgA nephropathy and Henoch–Schönlein syndrome. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. Philadelphia: Lippincott-Raven Publishers; 1998, p. 479–539. Emancipator SN. IgA nephropathy and Henoch–Schönlein syndrome. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. Philadelphia: Lippincott-Raven Publishers; 1998, p. 479–539.
4.
go back to reference Berger J, Hinglais N. Les depots intercapillaires d’IgA-IgG (intercapillary deposits of IgA-IgG). J Urol Nephrol. 1968;74:694–5. Berger J, Hinglais N. Les depots intercapillaires d’IgA-IgG (intercapillary deposits of IgA-IgG). J Urol Nephrol. 1968;74:694–5.
5.
go back to reference Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980;66:1432–6.PubMedCrossRef Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980;66:1432–6.PubMedCrossRef
6.
go back to reference Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol. 1999;29:53–72. Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol. 1999;29:53–72.
7.
go back to reference Novak J, Julian BA, Tomana M, Mestecky J. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol. 2001;21:310–27.PubMedCrossRef Novak J, Julian BA, Tomana M, Mestecky J. Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol. 2001;21:310–27.PubMedCrossRef
8.
go back to reference Kanemoto K, Tobita N, Anzai M, Matsumura C, Udagawa J, Kitamura H, et al. Multilateral investigation of IgA-IgG co-deposition in pediatric IgA nephropathy and Henoch–Schonlein purpura nephritis. Jpn J Pediatric Nephrol. 2009;2009(22):26–31. Kanemoto K, Tobita N, Anzai M, Matsumura C, Udagawa J, Kitamura H, et al. Multilateral investigation of IgA-IgG co-deposition in pediatric IgA nephropathy and Henoch–Schonlein purpura nephritis. Jpn J Pediatric Nephrol. 2009;2009(22):26–31.
9.
go back to reference Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007; 50:927–37. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007; 50:927–37.
10.
go back to reference Matsuo S. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Jpn J Nephrol. 2011;53:123–35. Matsuo S. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Jpn J Nephrol. 2011;53:123–35.
11.
go back to reference Haas M. IgA nephropathy and Henoch–Schönlein purpura nephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney, 6th edn. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 423–86. Haas M. IgA nephropathy and Henoch–Schönlein purpura nephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney, 6th edn. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 423–86.
12.
go back to reference Okada K, Funai M, Morimoto Y, Kagami S, Yano I, Kawakami K. IgA nephropathy in Japanese children and adults: a comparative study of clinicopathological features. Am J Nephrol. 1990;10:191–7.PubMedCrossRef Okada K, Funai M, Morimoto Y, Kagami S, Yano I, Kawakami K. IgA nephropathy in Japanese children and adults: a comparative study of clinicopathological features. Am J Nephrol. 1990;10:191–7.PubMedCrossRef
13.
go back to reference Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119:1668–77.PubMed Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119:1668–77.PubMed
14.
go back to reference Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81.PubMedCrossRef Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81.PubMedCrossRef
15.
go back to reference Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005;67:504–13.PubMedCrossRef Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005;67:504–13.PubMedCrossRef
16.
go back to reference Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney Int. 2011;80:79–87.PubMedCrossRef Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney Int. 2011;80:79–87.PubMedCrossRef
17.
go back to reference D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24:179–96. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24:179–96.
18.
go back to reference Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–42.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–42.PubMedCrossRef
19.
go back to reference Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.PubMedCrossRef Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.PubMedCrossRef
20.
go back to reference Roberts ISD, Cook HT, Troyanov S, Alpers C, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology, definition, correlation, and reproducibility. Kidney Int. 2009;76:546–56.PubMedCrossRef Roberts ISD, Cook HT, Troyanov S, Alpers C, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology, definition, correlation, and reproducibility. Kidney Int. 2009;76:546–56.PubMedCrossRef
21.
go back to reference Nieuwhof C, Kruytzer M, Frederiks P. Van Breda Vriesman PJ. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis. 1998;31:962–70.PubMedCrossRef Nieuwhof C, Kruytzer M, Frederiks P. Van Breda Vriesman PJ. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis. 1998;31:962–70.PubMedCrossRef
22.
go back to reference Van Dixhoorn MG, Sato T, Muizert Y, van Gijlswijk-Janssen DJ, De Heer E, Daha MR. Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation. Kidney Int. 2000;58:90–9.PubMedCrossRef Van Dixhoorn MG, Sato T, Muizert Y, van Gijlswijk-Janssen DJ, De Heer E, Daha MR. Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation. Kidney Int. 2000;58:90–9.PubMedCrossRef
23.
go back to reference Bellur S, Troyanov S, Cook HT. Roberts ISD on behalf of a working group of the international IgA nephropathy network and the renal pathology society. Nephrol Dial Transpl. 2011;26:2533–6.CrossRef Bellur S, Troyanov S, Cook HT. Roberts ISD on behalf of a working group of the international IgA nephropathy network and the renal pathology society. Nephrol Dial Transpl. 2011;26:2533–6.CrossRef
Metadata
Title
Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy
Authors
Yukihiro Wada
Hiroaki Ogata
Yui Takeshige
Akiko Takeshima
Noriyo Yoshida
Masahiro Yamamoto
Hidetoshi Ito
Eriko Kinugasa
Publication date
01-02-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0660-0

Other articles of this Issue 1/2013

Clinical and Experimental Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine